Reported Tuberculosis in the United States, 2018

Return to Main Menu

Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 20161

Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2016
Reporting Area Total Cases Therapy ≤1 Year Indicated2,3,4 Therapy >1 Year Indicated3,5
No. COT ≤1 year(%) COT(%) No. COT(%)
United States 9,253 7,582 (89.2) (95.6) 500 (93.2)
Alabama 112 97 (86.6) (94.8) 1 (100.0)
Alaska 57 54 (88.9) (90.7) 0
Arizona 188 135 (87.4) (95.6) 8 (100.0)
Arkansas 91 70 (78.6) (85.7) 3 (100.0)
California 2,058 1,647 (88.2) (96.4) 106 (91.5)
Colorado 64 46 (89.1) (91.3) 3 (100.0)
Connecticut 52 41 (97.6) (97.6) 4 (100.0)
Delaware 16 14 (100.0) (100.0) 1 (100.0)
District of Columbia 25 19 (94.7) (100.0) 3 (100.0)
Florida 639 535 (93.1) (96.6) 29 (93.1)
Georgia 302 243 (89.3) (95.5) 14 (85.7)
Hawaii 119 102 (99.0) (100.0) 8 (100.0)
Idaho 18 15 (93.3) (93.3) 0
Illinois 341 275 (92.0) (97.8) 21 (95.2)
Indiana 109 91 (92.3) (98.9) 5 (100.0)
Iowa 48 40 (87.5) (92.5) 4 (100.0)
Kansas 39 37 (91.9) (100.0) 1 (100.0)
Kentucky 91 77 (96.1) (100.0) 3 (100.0)
Louisiana 128 112 (75.9) (91.1) 4 (25.0)
Maine 23 21 (95.2) (100.0) 0
Maryland 221 182 (93.4) (97.8) 14 (100.0)
Massachusetts 190 156 (88.5) (98.1) 8 (100.0)
Michigan 133 115 (94.8) (97.4) 5 (80.0)
Minnesota 168 138 (94.2) (95.7) 16 (93.8)
Mississippi 61 47 (89.4) (95.7) 7 (71.4)
Missouri 99 88 (78.4) (81.8) 3 (100.0)
Montana 4 4 (100.0) (100.0) 0
Nebraska 28 25 (56.0) (72.0) 3 (66.7)
Nevada 55 43 (95.3) (95.3) 4 (100.0)
New Hampshire 15 10 (100.0) (100.0) 3 (100.0)
New Jersey 294 242 (93.8) (97.9) 13 (100.0)
New Mexico 39 29 (89.7) (96.6) 2 (100.0)
New York State6 202 161 (95.7) (100.0) 16 (93.8)
New York City 556 447 (93.3) (97.3) 52 (94.2)
North Carolina 219 189 (91.0) (96.3) 15 (100.0)
North Dakota 22 21 (90.5) (95.2) 1 (100.0)
Ohio 142 117 (76.9) (84.6) 9 (88.9)
Oklahoma 78 59 (94.9) (96.6) 3 (100.0)
Oregon 70 59 (79.7) (89.8) 4 (100.0)
Pennsylvania 173 142 (77.5) (92.3) 12 (91.7)
Rhode Island 12 8 (87.5) (100.0) 3 (100.0)
South Carolina 102 83 (94.0) (97.6) 8 (100.0)
South Dakota 12 9 (88.9) (88.9) 1 (100.0)
Tennessee 103 86 (95.3) (100.0) 7 (100.0)
Texas 1,247 1,046 (84.8) (93.2) 51 (88.2)
Utah 20 18 (94.4) (100.0) 0
Vermont 6 5 (100.0) (100.0) 0
Virginia 203 172 (92.4) (97.1) 10 (100.0)
Washington 204 165 (92.1) (95.8) 9 (100.0)
West Virginia 14 11 (81.8) (90.9) 1 (100.0)
Wisconsin 40 34 (85.3) (100.0) 2 (100.0)
Wyoming 1 0 0
American Samoa7 1 1 (0.0) (0.0) 0
Fed. States of Micronesia7 134 124 (96.0) (96.0) 2 (100.0)
Guam7 73 64 (84.4) (87.5) 2 (100.0)
Marshall Islands 178 157 (57.3) (58.0) 3 (66.7)
N. Mariana Islands7 28 25 (92.0) (92.0) 0
Puerto Rico7 69 52 (88.5) (96.2) 3 (66.7)
Republic of Palau7 23 19 (84.2) (89.5) 0
U.S. Virgin Islands7 0 0 0

1Most recent year for which data are available.
2In the United States, initial isolate susceptible to rifampin (n = 5,635) or susceptibility unknown (n = 98); culture negative (n = 1,476); culture status unknown (n = 359).
3Number of cases among persons alive at diagnosis, with an initial regimen of ≥1 drug prescribed. Percentages for United States overall are based on 52 reporting areas (50 U.S. states, New York City, and the District of Columbia).
4Therapy ≤1 year indicated among persons alive at diagnosis with an initial regimen of ≥1 drug prescribed, who did not die ≤1 year after initiating therapy. Excludes persons with initial isolate rifampin-resistant, or patient with bone or joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (aged ≤14 years) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who moved out of the country ≤1 year after initiating treatment.
5Initial isolate rifampin-resistant, or patient with meningeal disease or bone or joint disease, or disease of the central nervous system, or pediatric patient (aged ≤14 years) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who did not move out of the country or die during treatment.
6Excludes New York City.
7Not included in U.S. totals.

Note:
See Technical Notes.

Ellipses (…) indicate that the percentage cannot be calculated, and the denominator is 0.

Table Printing Tips  pdf icon pdf icon[PDF – 870 KB]

Page last reviewed: September 6, 2019